Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Ascendis Pharma A/S has received a consensus recommendation of "Moderate Buy" from 16 analysts, with 15 issuing buy ratings and one recommending a sell.
• The average one-year price target for the company's stock is approximately $244.64, with recent reports indicating targets as high as $254.00 from Stifel Nicolaus.
• In its last earnings report, Ascendis Pharma reported a loss of ($0.93) per share, exceeding analyst expectations, while revenue reached $216.28 million.

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and fifteen have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $244.6429.

ASND has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Bank of America upped their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price target for the company. Cantor Fitzgerald upped their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Finally, Wall Street Zen downgraded shares of Ascendis Pharma A/S from a "buy" rating to a "hold" rating in a research report on Friday, September 5th.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company's stock valued at $249,000 after acquiring an additional 55 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 0.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company's stock valued at $2,103,000 after acquiring an additional 73 shares in the last quarter. Main Management ETF Advisors LLC grew its stake in Ascendis Pharma A/S by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,864 shares of the biotechnology company's stock valued at $1,012,000 after acquiring an additional 96 shares in the last quarter. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 15.2% during the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company's stock valued at $146,000 after acquiring an additional 97 shares in the last quarter. Finally, Gilbert & Cook Inc. grew its stake in Ascendis Pharma A/S by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 6,750 shares of the biotechnology company's stock valued at $1,165,000 after acquiring an additional 131 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

ASND opened at $209.55 on Friday. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $216.45. The company has a fifty day moving average of $197.03 and a two-hundred day moving average of $175.65. The stock has a market capitalization of $12.93 billion, a price-to-earnings ratio of -40.61 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.